Skip to main content
. 2015 Oct 29;6:248. doi: 10.3389/fphar.2015.00248

Table 5.

High frequency H-bonds at anti-VEGF/VEGFA interfaces.

Anti-VEGF/VEGFA
Ranibizumab Tyr102/Glu93; Tyr101/Glu93; Tyr101/Glu79; Ser106/His90; Tyr99/Glu87; Tyr96/Glu87; Tyr34/Glu89; Thr53/Glu89; Tyr54/Tyr21; Trp50/His89.
Fab-bevacizumab His101/Glu93; Tyr102/Glu93; Ser106/His90; Thr53/Gln89; Tyr54/Tyr21.
VEGFR1d2_R2d3 Arg96/Asp93; Gln97/Lys107; Glu73/Arg105; Glu73/Arg103.

In the couple X/Y, X, and Y are respectively the residues of anti-angiogenic agent and VEGFA, involved in the H-bond.